Navigation Links
MEI Pharma CEO to Present at Stifel Healthcare Conference
Date:9/5/2013

SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a.m. Eastern time from the Four Seasons Hotel in Boston. A live webcast of the presentation can be accessed at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.

(Logo:  http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
2. Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
3. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
5. Pharmaceutical and Medical Device Patent Portfolio Acquisition Opportunities from ICAP Patent Brokerage
6. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
7. David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
8. Isis Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
9. Synergy Between Food and Pharma Driving South Americas Economy
10. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
11. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- The report " Automated Breast Ultrasound System (ABUS) Market ... User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... Germany , UK, France , ... China , Japan , India ... Saudi Arabia , UAE, South Africa ), Application ...
(Date:1/18/2017)... 2017  Tarix Orphan LLC today announced that the ... Pediatric Disease (RPD) designation for the company,s drug candidate ... (RDEB), a rare genetic skin disorder. There are currently ... to supportive care. "The RPD designation for ... granted by the FDA in this indication," said ...
(Date:1/18/2017)... -- Astellas Pharma Inc. (President and CEO: Yoshihiko ... in Access Accelerated, a global, multi-stakeholder initiative to ... and treatment in low-income and lower-middle income countries. ... in collaboration with the World Bank Group and ... will work towards the United Nations Sustainable Development ...
Breaking Medicine Technology:
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... Maryland Fischell Department of Bioengineering are collaborating on a research project focused on ... bioengineering, the project seeks to use nanotechnology to control the disease without compromising ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... industry’s leading journal and most-read publication among specialty pharmacists and pharmacy professionals, ... through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of ...
(Date:1/18/2017)... ... 18, 2017 , ... A Palm Beach doctor plans to run the 2017 ... that provides free surgery to poor children suffering from cleft lip and cleft palate. ... run to support the efforts of the American Heart Association and the Leukemia and ...
(Date:1/18/2017)... , ... January 18, 2017 , ... The Portee Insurance ... families and business owners in central Maryland and the DC region, is inaugurating a ... kills 787,000 people nationally every year, making it the #1 killer in America. However, ...
Breaking Medicine News(10 mins):